Patient-Derived Xenograft/PDX Model Market
Global Patient-Derived Xenograft/PDX Model Market Size, Share & Trends Analysis Report By Type (Mice Model, and Rat Model) By Tumor Models (Gynecological, Gastrointestinal, Respiratory Tumor Model and Others) By Application (Preclinical drug development, Biomarker analysis, and Basic Cancer Research) By End-User (Pharmaceutical & Biotechnology Companies, CROs, and Academic & Research Institutions) Forecast, 2021-2027
The global PDX Model market is anticipated to grow at a CAGR of around 15.5% during the forecast period (2021-2027). The rising prevalence of cancer in major economies is the key reason driving the demand for PDX models. As per the estimates from the International Agency for Research on Cancer (IARC), in 2018, 17.0 million new cases, and 9.5 million mortalities were estimated. It is also expected that this burden will grow to 27.5 million new cases and 16.3 million deaths by 2040. Due to this increasing cancer prevalence, studies on cancer research are growing globally. The PDX models are increasingly used in translational cancer research. The adoption of different types of PDX models such as mice and rate models for study various types of tumors by researchers is creating a wide scope for PDX models. In addition, PDX models are shown to be predictive of clinical outcomes and are being used for preclinical drug evaluation, biomarker identification, biologic studies, and personalized medicine strategies. This led to the growth of the market. Apart from this, the increasing demand for personalized medicines, growing government support for cancer research and increasing expenditure by pharmaceutical companies on R&D activities also boosting the growth of the market. For instance, in 2019, the American Cancer Society invested around $145.9 million in cancer research.
Moreover, the stringent regulations by the government regarding the use of animal models in cancer research, the high cost of personalized PDX models, and the limitations of PDX models are the factors that may restrain the market growth during the forecast period. Moreover, the development of next-generation PDX models with human immune systems may offer lucrative growth opportunities to the market during the forecast period.
Segmental Outlook
The global PDX model market is segmented based on type, tumor models, application, and end-user. Based on type, the market is bifurcated into mice model, and rate model. The rat model segment is accounted for the largest growth rate during the forecast period. Based on tumor models, the market is again classified into gynecological tumor model, gastrointestinal tumor model, respiratory tumor model, and others. Among these, the respiratory tumor models segment leads the market during the forecast period. Similarly, based on application, the market is categorized into preclinical drug development, biomarker analysis, and basic cancer research. The preclinical drug development segment held the largest share in the market, and it is projected to grow at a significant CAGR during the forecast period. Whereas, based on end-user, the market is further divided into pharmaceutical & biotechnology companies, CROs, hospitals and surgical centers, academic & research institutions, and others. Among these, the CRO segment is expected to be the fastest-growing during the forecast period owing to the increasing pharmaceutical companies hiring for CRO for the outsourcing of their preclinical studies.
Global PDX Model Market Share by Application, 2020 (%)
The Preclinical Drug Development Segment is Expected to Account Significant Share in Global PDX Model Market
Among applications of the PDX model, the preclinical drug development segment is projected to hold a significant share in the market during the forecast period. The preclinical drug development activities include the development regarding the preparation of drugs and related clinical plans, documentation, and approvals from the FDA to the drugs. Due to increasing cancer prevalence globally, the number of clinical trials in oncology is also rising. These are the major factors creating the demand for various types of PDX models for cancer reach and related drug developments. The PDX models are increasingly used by researchers in cancer research as a tool to inform cancer biology and drug response. During drug development, researchers optimize PDX models in both hypothesis testing and hypothesis generation such as predictive biomarker discovery. With the rise in the number of cancer clinical trials, the demand for PDX models will also be expected to rise, this will drive the growth of the market during the forecast period.
Regional Outlook
Geographically, the global PDX Model market is classified into four major regions including North America (the US and Canada), Europe (UK, Germany, France, Italy, Spain, and Rest of Europe), Asia-Pacific (India, China, Japan, South Korea, ASEAN, and Rest of Asia-Pacific), and Rest of the World (Latin America and the Middle East and Africa (MEA)). Asia-Pacific is the region that is expected to be the fastest-growing during the forecast period. Increasing spending on R&D by pharmaceutical companies and increasing government initiatives for cancer research by providing funding are the factors accelerating the growth of the market during the forecast period.
Global PDX Model Market Growth, By Region 2021-2027
North America Holds the Largest Share in Global PDX Model Market
Geographically, North America held the largest share in the global PDX model market in 2020, and it is estimated that it will dominate the market again by accounting significant share in the market during the forecast period. The presence of a large cancer patient base, growing cancer research, development in healthcare infrastructure, and government initiatives regarding cancer awareness are the prominent factors driving the regional growth. The US in North America accounted for the high share in the market owing to the presence of major players and their contribution towards the market growth. The major players such as Champions Oncology, Inc., The Jackson Laboratory, Charles River Laboratories, among others are the key players operating in the PDX models market in the US.
Market Players Outlook
The key players in the PDX Model market contributing significantly by providing different types of products and increasing their geographical presence across the globe. The key players of the market include Champions Oncology, Inc., Charles River Laboratories International, Inc., Envigo RMS LLC, EPO Berlin-Buch GmbH, Genesis Biotechnology Group, Hera Biolabs, JSR Corp, among others. These market players are adopting several market strategies including product launch and approvals, merger and acquisition, partnership collaboration, business, and capacity expansion, and others. For instance, in August 2021, Champions Oncology, Inc., announced the strategic collaboration with AstraZeneca PLC to develop novel cohorts of PDX models. The model was used by AstraZeneca PLC in their oncology R&D programs for breast and lung cancer.
The Report Covers
- Market value data analysis of 2020 and forecast to 2027.
- Annualized market revenues ($ million) for each market segment.
- Country-wise analysis of major geographical regions.
- Key companies operating in the global PDX Model market. Based on the availability of data, information related to pipeline products, and relevant news is also available in the report.
- Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
- Analysis of market entry and market expansion strategies.
- Competitive strategies by identifying ‘who-stands-where’ in the market.
1. Report Summary
• Current Industry Analysis and Growth Potential Outlook
• Impact of COVID-19 on the Global PDX Model Industry
• Recovery Scenario of Global PDX Model Industry
1.1. Research Methods and Tools
1.2. Market Breakdown
1.2.1. By Segments
1.2.2. By Geography
2. Market Overview and Insights
2.1. Scope of the Report
2.2. Analyst Insight & Current Market Trends
2.2.1. Key Findings
2.2.2. Trade Analysis
2.2.3. Porter’s Analysis
2.2.4. Conclusion
3. Competitive Landscape
3.1. Key Company Analysis
3.1.1. Overview
3.1.2. Financial Analysis
3.1.3. SWOT Analysis
3.1.4. Recent Developments
3.2. Key Strategy Analysis
3.3. Impact of COVID-19 on key players
4. Market Determinants
4.1. Motivators
4.2. Restraints
4.3. Opportunities
5. Market Segmentation
5.1. Global PDX Model Market, ByType
5.1.1. Mice Model
5.1.2. Rat Model
5.2. Global PDX Model Market, ByTumor Models
5.2.1. Gynecological Tumor Model
5.2.2. Gastrointestinal Tumor Model
5.2.3. Respiratory Tumor Model
5.2.4. Others
5.3. Global PDX Model Market, By Application
5.3.1. Preclinical drug development
5.3.2. Biomarker analysis
5.3.3. Basic Cancer Research
5.4. Global PDX Model Market, By End-User
5.4.1. Pharmaceutical & Biotechnology Companies
5.4.2. Contract research organizations (CROs)
5.4.3. Academic & Research Institutions
6. Regional Analysis
6.1. North America
6.1.1. United States
6.1.2. Canada
6.2. Europe
6.2.1. UK
6.2.2. Germany
6.2.3. Italy
6.2.4. Spain
6.2.5. France
6.2.6. Rest of Europe
6.3. Asia-Pacific
6.3.1. China
6.3.2. India
6.3.3. Japan
6.3.4. South Korea
6.3.5. Rest of Asia-Pacific
6.4. Rest of the World
6.4.1. Latin America
6.4.2. Middle East & Africa
7. Company Profiles
7.1. Abnova Corp.
7.2. Aragen Life Sciences Pvt. Ltd.
7.3. Biocytogen
7.4. Champions Oncology, Inc.
7.5. Charles River Laboratories International, Inc.
7.6. Crown Bioscience Inc.,
7.7. Envigo RMS LLC
7.8. EPO Berlin-Buch GmbH
7.9. ExploraBioLabs
7.10. Genesis Biotechnology Group
7.11. Hera Biolabs
7.12. Horizon Discovery Ltd.
7.13. JSR Corp.
7.14. Living Tumor Laboratory
7.15. Oncodesign
7.16. Pharmatest Services
7.17. Shanghai LIDE Biotech Co., Ltd.
7.18. The Jackson Laboratory
7.19. Urosphere SAS
7.20. WuXiAppTec
7.21. XenTech SAS
1. GLOBAL PDX MODEL MARKET RESEARCH AND ANALYSIS BY TYPE, 2020-2027 ($ MILLION)
2. GLOBAL PDX MICE MODEL MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
3. GLOBAL PDX RAT MODEL MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
4. GLOBAL PDX MODEL MARKET RESEARCH AND ANALYSIS BY TUMORMODELS, 2020-2027 ($ MILLION)
5. GLOBAL GYNECOLOGICAL TUMOR PDXMODEL MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
6. GLOBAL GASTROINTESTINAL TUMOR PDX MODEL MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
7. GLOBAL RESPIRATORY TUMOR PDX MODEL MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
8. GLOBAL OTHERS TUMOR PDX MODEL MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
9. GLOBAL PDX MODEL MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2020-2027 ($ MILLION)
10. GLOBAL PDX MODEL IN PRECLINICAL DRUG DEVELOPMENT MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
11. GLOBAL PDX MODEL IN BIOMARKER ANALYSIS MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
12. GLOBAL PDX MODEL IN BASIC CANCER RESEARCH MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
13. GLOBAL PDX MODEL MARKET RESEARCH AND ANALYSIS BY END-USER, 2020-2027 ($ MILLION)
14. GLOBAL PDX MODEL FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES MODEL MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
15. GLOBAL PDX MODEL FOR CROs MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
16. GLOBAL PDX MODEL FOR HOSPITALS AND SURGICAL CENTERS MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
17. GLOBAL PDX MODEL FOR OTHER END-USERS MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
18. NORTH AMERICAN PDX MODEL MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2020-2027 ($ MILLION)
19. NORTH AMERICAN PDX MODEL MARKET RESEARCH AND ANALYSIS BY TYPE,2020-2027 ($ MILLION)
20. NORTH AMERICAN PDX MODEL MARKET RESEARCH AND ANALYSIS BY TUMORMODELS, 2020-2027 ($ MILLION)
21. NORTH AMERICAN PDX MODEL MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2020-2027 ($ MILLION)
22. NORTH AMERICAN PDX MODEL MARKET RESEARCH AND ANALYSIS BY END-USER, 2020-2027 ($ MILLION)
23. EUROPEAN PDX MODEL MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2020-2027 ($ MILLION)
24. EUROPEAN PDX MODEL MARKET RESEARCH AND ANALYSIS BY TYPE, 2020-2027 ($ MILLION)
25. EUROPEAN PDX MODEL MARKET RESEARCH AND ANALYSIS BY TUMORMODELS, 2020-2027 ($ MILLION)
26. EUROPEAN PDX MODEL MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2020-2027 ($ MILLION
27. EUROPEAN PDX MODEL MARKET RESEARCH AND ANALYSIS BY END-USER, 2020-2027 ($ MILLION
28. ASIA-PACIFIC PDX MODEL MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2020-2027 ($ MILLION)
29. ASIA-PACIFIC PDX MODEL MARKET RESEARCH AND ANALYSIS BY TYPE, 2020-2027 ($ MILLION)
30. ASIA-PACIFIC PDX MODEL MARKET RESEARCH AND ANALYSIS BY TUMORMODELS, 2020-2027 ($ MILLION)
31. ASIA-PACIFIC PDX MODEL MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2020-2027 ($ MILLION)
32. ASIA-PACIFIC PDX MODEL MARKET RESEARCH AND ANALYSIS BY END-USER, 2020-2027 ($ MILLION)
33. REST OF THE WORLD PDX MODEL MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2020-2027 ($ MILLION)
34. REST OF THE WORLD PDX MODEL MARKET RESEARCH AND ANALYSIS BY TYPE, 2020-2027 ($ MILLION)
35. REST OF THE WORLD PDX MODEL MARKET RESEARCH AND ANALYSIS BY TUMORMODELS, 2020-2027 ($ MILLION)
36. REST OF THE WORLD PDX MODEL MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2020-2027 ($ MILLION)
37. REST OF THE WORLD PDX MODEL MARKET RESEARCH AND ANALYSIS BY END-USER, 2020-2027 ($ MILLION)
1. IMPACT OF COVID-19 ON GLOBAL PDX MODEL MARKET, 2020-2027 (% MILLION)
2. IMPACT OF COVID-19 ON GLOBAL PDX MODEL MARKET BY SEGMENT, 2020-2027 (% MILLION)
3. RECOVERY OF GLOBAL PDX MODEL MARKET, 2020-2027 (%)
4. GLOBAL PDX MODEL MARKET SHARE BY TYPE,2020 VS 2027 (%)
5. GLOBAL PDX MODEL MARKET SHARE BY TUMORMODELS, 2020 VS 2027 (%)
6. GLOBAL PDX MODEL MARKET SHARE BY APPLICATION, 2020 VS 2027 (%)
7. GLOBAL PDX MODEL MARKET SHARE BY END-USER, 2020 VS 2027 (%)
8. GLOBAL PDX MODEL MARKET SHARE BY GEOGRAPHY, 2020 VS 2027 (%)
9. GLOBAL PDX MICE MODEL MARKET SHARE BY REGION, 2020 VS 2027 (%)
10. GLOBAL PDX RAT MODEL MARKET SHARE BY REGION, 2020 VS 2027 (%)
11. GLOBAL GYNECOLOGICAL TUMOR PDX Model MARKET SHARE BY REGION, 2020 VS 2027 (%)
12. GLOBAL GASTROINTESTINAL TUMOR PDX MODEL SHARE BY REGION, 2020 VS 2027 (%)
13. GLOBAL RESPIRATORY TUMOR PDX MODEL MARKET SHARE BY REGION, 2020 VS 2027 (%)
14. GLOBAL OTHERS TUMOR PDX MODEL MARKET SHARE BY REGION, 2020 VS 2027 (%)
15. GLOBAL PDX MODEL IN PRECLINICAL DRUG DEVELOPMENT MARKET SHARE BY REGION, 2020 VS 2027 (%)
16. GLOBAL PDX MODEL IN BIOMARKER ANALYSIS MARKET SHARE BY REGION, 2020 VS 2027 (%)
17. GLOBAL PDX MODEL IN BASIC CANCER RESEARCH MARKET SHARE BY REGION, 2020 VS 2027 (%)
18. GLOBAL PDX MODEL FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES MODEL MARKET SHARE BY REGION, 2020 VS 2027 (%)
19. GLOBAL PDX MODEL FOR CROs MARKET SHARE BY REGION, 2020 VS 2027 (%)
20. GLOBAL PDX MODEL FOR HOSPITALS AND SURGICAL CENTERS MARKET SHARE BY REGION, 2020 VS 2027 (%)
21. GLOBAL PDX MODEL FOR OTHER END-USERS MARKET SHARE BY REGION, 2020 VS 2027 (%)
22. US PDX MODEL MARKET SIZE, 2020-2027 ($ MILLION)
23. CANADA PDX MODEL MARKET SIZE, 2020-2027 ($ MILLION)
24. UK PDX MODEL MARKET SIZE, 2020-2027 ($ MILLION)
25. FRANCE PDX MODEL MARKET SIZE, 2020-2027 ($ MILLION)
26. GERMANY PDX MODEL MARKET SIZE, 2020-2027 ($ MILLION)
27. ITALY PDX MODEL MARKET SIZE, 2020-2027 ($ MILLION)
28. SPAIN PDX MODEL MARKET SIZE, 2020-2027 ($ MILLION)
29. REST OF EUROPE PDX MODEL MARKET SIZE, 2020-2027 ($ MILLION)
30. INDIA PDX MODEL MARKET SIZE, 2020-2027 ($ MILLION)
31. CHINA PDX MODEL MARKET SIZE, 2020-2027 ($ MILLION)
32. JAPAN PDX MODEL MARKET SIZE, 2020-2027 ($ MILLION)
33. SOUTH KOREA PDX MODEL MARKET SIZE, 2020-2027 ($ MILLION)
34. REST OF ASIA-PACIFIC PDX MODEL MARKET SIZE, 2020-2027 ($ MILLION)
35. REST OF THE WORLD PDX MODEL MARKET SIZE, 2021-2027($ MILLION
